Zobrazeno 1 - 10
of 47
pro vyhledávání: ''
Autor:
Geraldine M. Jacobson, Gary Marano, Timothy D. Eubank, Malcolm D. Mattes, Patrick C. Ma, Mohammed Almubarak, Sijin Wen
Publikováno v:
Clin Lung Cancer
INTRODUCTION/BACKGROUND: This study assessed the safety and systemic (abscopal) response from the addition of local stereotactic body radiation therapy (SBRT) to checkpoint inhibitor (CPI) immunotherapy in patients with metastatic non-small cell lung
Autor:
Tomonori Makiguchi, Masamichi Itoga, Yoshiomi Hatayama, Hisashi Tanaka, Kageaki Taima, Junichi Yokouchi, Yoshiko Ishioka, Fumihiko Okumura, Yukihiro Hasegawa, Toshihiro Shiratori, Chiori Tabe, Sadatomo Tasaka, Masahiko Aoki
Publikováno v:
Clinical Lung Cancer. 22:42-48
Background Concurrent chemoradiotherapy (CCRT) is the standard treatment for patients with locally advanced non–small-cell lung cell cancer (LA-NSCLC). We conducted a phase I/II study of biweekly carboplatin and nab-paclitaxel (nab-PTX) with radiot
Autor:
Satoshi Ikeda, Kentaro Tanaka, Masafumi Sata, Hiroshi Tanaka, Eiki Ichihara, Takeharu Yamanaka, Masaki Kanazu, Yuichi Takiguchi, Hiroaki Okamoto, Hidehito Horinouchi, Yasuhiro Goto, Koichi Hagiwara, Satoru Miura, Terufumi Kato
Publikováno v:
Clinical Lung Cancer. 21:e592-e596
We describe the treatment rationale and design of our randomized phase III study, the ACHILLES trial (Japan Registry of Clinical Trials: jRCTs031180175). The aim of this study is to investigate the superiority of afatinib over chemotherapy as first-l
Autor:
Haruko Daga, Junji Kishimoto, Shunichi Sugawara, Osamu Hataji, Hidetoshi Hayashi, Yoshimasa Shiraishi, Katsuya Hirano, Koichi Azuma, Motoko Tachihara, Takashi Seto, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Isamu Okamoto, Tetsuya Mitsudomi, Kentaro Tanaka
Publikováno v:
Clinical Lung Cancer. 21:472-476
Background First-line treatment of non–small-cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with an immune checkpoint inhibitor (ICI). Bevacizumab is expected to enhance not only chemotherapy but al
Autor:
Virginia Pardo-Marqués, M. Teresa Agulló-Ortuño, Laura Ojeda, Lara Iglesias, Irene Ferrer, Óscar Gómez-Martín, Luis Paz-Ares, Santiago Ponce, Inmaculada García-Ruiz
Publikováno v:
Clinical Lung Cancer. 21:75-85
Background Immunotherapy is a promising cancer treatment, but surrogate biomarkers of clinical efficacy have not been fully validated. The aim of this work was to evaluate several biomarkers as predictors of response to nivolumab monotherapy in patie
Autor:
Filippo de Braud, Mirko Marabese, Elisa Caiola, Giancarlo Pruneri, Valter Torri, Monica Ganzinelli, Elena Tamborini, Rosaria Gallucci, Giulia Galli, Mario P. Colombo, Massimo Moro, Marina Chiara Garassino, Alessandra Fabbri, Gabriella Sozzi, Angela Maria Rizzo, Lital Hollander, Diego Signorelli, Tiziana Triulzi, Massimo Broggini, Giulia Vandoni, Paola Antonia Corsetto, Cecilia Gavazzi, Claudio Vernieri
Publikováno v:
Clinical Lung Cancer. 20:e413-e417
Advanced lung adenocarcinoma with inactive liver kinase B1 (LKB1) tumor suppressor protein is associated with poor response to immune checkpoint inhibitors and molecularly targeted agents, and with dismal patient prognosis. LKB1 is a central orchestr
Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib
Autor:
D. Ross Camidge, Derek E. Smith, Dara L. Aisner, Adrie van Bokhoven, Theresa A. Boyle, Dexiang Gao, Hui Yu, Emily R. York, Scott Leedy, Lynn E. Heasley, Terry L. Ng, Fred R. Hirsch
Publikováno v:
Clinical Lung Cancer. 20:e39-e51
Introduction Preclinically, high epidermal growth factor receptor 1 (FGFR1) messenger RNA (FGFR1-MRNA) and FGFR1 amplification (FGFR1-AMP) predicted sensitivity to fibroblast growth factor receptor inhibitors in non–small-cell lung cancer and small
A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non–small-cell Lung Cancer
Autor:
Xiaoxia Chen, Anwen Xiong, Guanghui Gao, Shengxiang Ren, Jing Zhao, Weijing Cai, Caicun Zhou, Wei Li, Fengying Wu, Shijia Zhang, Chunxia Su, Fei Zhou
Publikováno v:
Clinical Lung Cancer. 19:e831-e842
Objectives Apatinib exhibits broad-spectrum antitumor activities by selectively inhibiting vascular endothelial growth factor receptor-2. This study evaluated the efficacy and safety of apatinib in patients with advanced non-squamous non–small-cell
Autor:
Haojie Li, Ashwini Arunachalam, Gregory M. Lubiniecki, Ramon E. Camacho, Marisa A. Bittoni, David P. Carbone, Xiting Cao, Yichen Zhong
Publikováno v:
Clinical Lung Cancer. 19:e783-e799
Introduction Real-world data on current treatment practices for non–small-cell lung cancer (NSCLC) are needed to understand the place in therapy and potential economic impact of newer therapies. Patients and Methods This retrospective cohort study
Autor:
Takashi Seto, Hiroaki Okamoto, Miyako Satouchi, Hiroshi Tanaka, Masao Harada, Keisuke Tomii, Kazuma Kishi, Toshiyuki Sawa, Yuichiro Ohe, Naoyuki Nogami, Junki Mizusawa, Koichi Goto, Yuka Fujita, Takashi Kasai, Yuichiro Takeda, Koji Takeda, Shinji Atagi, Toshiaki Takahashi, Kazuhiko Nakagawa, Satoshi Ishikura
Publikováno v:
Clinical Lung Cancer. 19:e619-e627
Introduction In the phase III JCOG0301 trial, chemoradiotherapy (CRT) with daily low-dose carboplatin showed significant benefits in elderly patients with locally advanced non–small-cell lung cancer (NSCLC) compared with radiotherapy (RT) alone. Ho